286 studies found for:    "Breast cancer male"
Hide Display Options

Display Options

Study Details
Participant Details
Identifiers
Dates
Rank Status Study
1 Active, not recruiting An Observational Registry-Based Study of a Potential Link Between Finasteride (MK-0906) and Male Breast Cancer in 4 Nordic Countries (MK-0906-162/2003.021)
Condition: Male Breast Cancer
Intervention: Drug: Finasteride
2 Recruiting A Prospective, Randomised, Multi-centre Phase II Study Evaluating the Adjuvant, Neoadjuvant or Palliative Treatmant With Tamoxifen +/- GnRH Analogue Versus Aromatase Inhibitor + GnRH Analogue in Male Breast Cancer Patients
Condition: Male Breast Cancer
Interventions: Drug: Tamoxifen;   Drug: Tamoxifen and GnRH analogue;   Drug: Exemestane and GnRH analogue
3 Completed Male Breast Cancer Summa Health System/Akron City Hospital Experience 1995-2007
Condition: Breast Cancer
Intervention:
4 Recruiting Vaccine Therapy in Treating Patients With Stage IV Hormone Receptor Positive Breast Cancer
Conditions: HER2-positive Breast Cancer;   Male Breast Cancer;   Recurrent Breast Cancer;   Stage IV Breast Cancer
Interventions: Biological: HER-2/neu peptide vaccine;   Other: laboratory biomarker analysis
5 Recruiting PD 0332991 in Treating Patients With Refractory Solid Tumors
Conditions: Adult Solid Tumor;   Adenocarcinoma of the Colon;   Adenocarcinoma of the Rectum;   Adult Central Nervous System Germ Cell Tumor;   Adult Teratoma;   Benign Teratoma;   Estrogen Receptor-negative Breast Cancer;   Estrogen Receptor-positive Breast Cancer;   Familial Testicular Germ Cell Tumor;   HER2-negative Breast Cancer;   HER2-positive Breast Cancer;   Male Breast Cancer;   Ovarian Immature Teratoma;   Ovarian Mature Teratoma;   Ovarian Monodermal and Highly Specialized Teratoma;   Progesterone Receptor-negative Breast Cancer;   Progesterone Receptor-positive Breast Cancer;   Recurrent Breast Cancer;   Recurrent Colon Cancer;   Recurrent Extragonadal Germ Cell Tumor;   Recurrent Extragonadal Non-seminomatous Germ Cell Tumor;   Recurrent Extragonadal Seminoma;   Recurrent Malignant Testicular Germ Cell Tumor;   Recurrent Melanoma;   Recurrent Ovarian Germ Cell Tumor;   Recurrent Rectal Cancer;   Stage III Extragonadal Non-seminomatous Germ Cell Tumor;   Stage III Extragonadal Seminoma;   Stage III Malignant Testicular Germ Cell Tumor;   Stage III Ovarian Germ Cell Tumor;   Stage IV Breast Cancer;   Stage IV Colon Cancer;   Stage IV Extragonadal Non-seminomatous Germ Cell Tumor;   Stage IV Extragonadal Seminoma;   Stage IV Melanoma;   Stage IV Ovarian Germ Cell Tumor;   Stage IV Rectal Cancer;   Testicular Immature Teratoma;   Testicular Mature Teratoma
Interventions: Drug: PD-0332991;   Other: pharmacological study
6 Recruiting Veliparib and Carboplatin in Treating Patients With HER2-Negative Metastatic Breast Cancer
Conditions: BRCA1 Mutation Carrier;   BRCA2 Mutation Carrier;   Estrogen Receptor-negative Breast Cancer;   Estrogen Receptor-positive Breast Cancer;   HER2-negative Breast Cancer;   Male Breast Cancer;   Progesterone Receptor-negative Breast Cancer;   Progesterone Receptor-positive Breast Cancer;   Stage IIIB Breast Cancer;   Stage IIIC Breast Cancer;   Stage IV Breast Cancer;   Triple-negative Breast Cancer
Interventions: Drug: veliparib;   Drug: carboplatin;   Other: fluorine F 18 fluorothymidine;   Procedure: positron emission tomography;   Other: laboratory biomarker analysis;   Other: pharmacological study
7 Active, not recruiting RO4929097 and Capecitabine in Treating Patients With Refractory Solid Tumors
Conditions: Adult Grade III Lymphomatoid Granulomatosis;   Adult Nasal Type Extranodal NK/T-cell Lymphoma;   AIDS-related Diffuse Large Cell Lymphoma;   AIDS-related Diffuse Mixed Cell Lymphoma;   AIDS-related Diffuse Small Cleaved Cell Lymphoma;   AIDS-related Immunoblastic Large Cell Lymphoma;   AIDS-related Lymphoblastic Lymphoma;   AIDS-related Peripheral/Systemic Lymphoma;   AIDS-related Primary CNS Lymphoma;   AIDS-related Small Noncleaved Cell Lymphoma;   Anaplastic Large Cell Lymphoma;   Angioimmunoblastic T-cell Lymphoma;   Cutaneous B-cell Non-Hodgkin Lymphoma;   Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue;   HER2-negative Breast Cancer;   HIV-associated Hodgkin Lymphoma;   Intraocular Lymphoma;   Male Breast Cancer;   Nodal Marginal Zone B-cell Lymphoma;   Post-transplant Lymphoproliferative Disorder;   Primary Central Nervous System Hodgkin Lymphoma;   Primary Central Nervous System Non-Hodgkin Lymphoma;   Recurrent Adult Burkitt Lymphoma;   Recurrent Adult Diffuse Large Cell Lymphoma;   Recurrent Adult Diffuse Mixed Cell Lymphoma;   Recurrent Adult Diffuse Small Cleaved Cell Lymphoma;   Recurrent Adult Grade III Lymphomatoid Granulomatosis;   Recurrent Adult Hodgkin Lymphoma;   Recurrent Adult Immunoblastic Large Cell Lymphoma;   Recurrent Adult Lymphoblastic Lymphoma;   Recurrent Adult T-cell Leukemia/Lymphoma;   Recurrent Breast Cancer;   Recurrent Colon Cancer;   Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma;   Recurrent Grade 1 Follicular Lymphoma;   Recurrent Grade 2 Follicular Lymphoma;   Recurrent Grade 3 Follicular Lymphoma;   Recurrent Mantle Cell Lymphoma;   Recurrent Marginal Zone Lymphoma;   Recurrent Mycosis Fungoides/Sezary Syndrome;   Recurrent Rectal Cancer;   Recurrent Small Lymphocytic Lymphoma;   Small Intestine Lymphoma;   Splenic Marginal Zone Lymphoma;   Stage III Adult Burkitt Lymphoma;   Stage III Adult Diffuse Large Cell Lymphoma;   Stage III Adult Diffuse Mixed Cell Lymphoma;   Stage III Adult Diffuse Small Cleaved Cell Lymphoma;   Stage III Adult Hodgkin Lymphoma;   Stage III Adult Immunoblastic Large Cell Lymphoma;   Stage III Adult Lymphoblastic Lymphoma;   Stage III Adult T-cell Leukemia/Lymphoma;   Stage III Colon Cancer;   Stage III Cutaneous T-cell Non-Hodgkin Lymphoma;   Stage III Grade 1 Follicular Lymphoma;   Stage III Grade 2 Follicular Lymphoma;   Stage III Grade 3 Follicular Lymphoma;   Stage III Mantle Cell Lymphoma;   Stage III Marginal Zone Lymphoma;   Stage III Mycosis Fungoides/Sezary Syndrome;   Stage III Rectal Cancer;   Stage III Small Lymphocytic Lymphoma;   Stage IIIA Breast Cancer;   Stage IIIB Breast Cancer;   Stage IIIC Breast Cancer;   Stage IV Adult Burkitt Lymphoma;   Stage IV Adult Diffuse Large Cell Lymphoma;   Stage IV Adult Diffuse Mixed Cell Lymphoma;   Stage IV Adult Diffuse Small Cleaved Cell Lymphoma;   Stage IV Adult Hodgkin Lymphoma;   Stage IV Adult Immunoblastic Large Cell Lymphoma;   Stage IV Adult Lymphoblastic Lymphoma;   Stage IV Adult T-cell Leukemia/Lymphoma;   Stage IV Breast Cancer;   Stage IV Colon Cancer;   Stage IV Cutaneous T-cell Non-Hodgkin Lymphoma;   Stage IV Grade 1 Follicular Lymphoma;   Stage IV Grade 2 Follicular Lymphoma;   Stage IV Grade 3 Follicular Lymphoma;   Stage IV Mantle Cell Lymphoma;   Stage IV Marginal Zone Lymphoma;   Stage IV Mycosis Fungoides/Sezary Syndrome;   Stage IV Rectal Cancer;   Stage IV Small Lymphocytic Lymphoma;   Unspecified Adult Solid Tumor, Protocol Specific;   Waldenström Macroglobulinemia
Interventions: Drug: gamma-secretase/Notch signalling pathway inhibitor RO4929097;   Drug: capecitabine;   Other: laboratory biomarker analysis
8 Completed Interleukin-12 and Trastuzumab in Treating Patients With Cancer That Has High Levels of HER2/Neu
Conditions: Advanced Adult Primary Liver Cancer;   Anaplastic Thyroid Cancer;   Bone Metastases;   Carcinoma of the Appendix;   Distal Urethral Cancer;   Fallopian Tube Cancer;   Gastrinoma;   Glucagonoma;   Inflammatory Breast Cancer;   Insulinoma;   Liver Metastases;   Localized Unresectable Adult Primary Liver Cancer;   Lung Metastases;   Male Breast Cancer;   Malignant Pericardial Effusion;   Malignant Pleural Effusion;   Metastatic Gastrointestinal Carcinoid Tumor;   Metastatic Parathyroid Cancer;   Metastatic Transitional Cell Cancer of the Renal Pelvis and Ureter;   Newly Diagnosed Carcinoma of Unknown Primary;   Occult Non-small Cell Lung Cancer;   Pancreatic Polypeptide Tumor;   Primary Peritoneal Cavity Cancer;   Proximal Urethral Cancer;   Pulmonary Carcinoid Tumor;   Recurrent Adenoid Cystic Carcinoma of the Oral Cavity;   Recurrent Adrenocortical Carcinoma;   Recurrent Adult Primary Liver Cancer;   Recurrent Anal Cancer;   Recurrent Bladder Cancer;   Recurrent Breast Cancer;   Recurrent Carcinoma of Unknown Primary;   Recurrent Cervical Cancer;   Recurrent Colon Cancer;   Recurrent Endometrial Carcinoma;   Recurrent Esophageal Cancer;   Recurrent Extrahepatic Bile Duct Cancer;   Recurrent Gallbladder Cancer;   Recurrent Gastric Cancer;   Recurrent Gastrointestinal Carcinoid Tumor;   Recurrent Islet Cell Carcinoma;   Recurrent Malignant Testicular Germ Cell Tumor;   Recurrent Mucoepidermoid Carcinoma of the Oral Cavity;   Recurrent Non-small Cell Lung Cancer;   Recurrent Ovarian Epithelial Cancer;   Recurrent Pancreatic Cancer;   Recurrent Parathyroid Cancer;   Recurrent Prostate Cancer;   Recurrent Rectal Cancer;   Recurrent Renal Cell Cancer;   Recurrent Salivary Gland Cancer;   Recurrent Small Intestine Cancer;   Recurrent Squamous Cell Carcinoma of the Larynx;   Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity;   Recurrent Squamous Cell Carcinoma of the Nasopharynx;   Recurrent Squamous Cell Carcinoma of the Oropharynx;   Recurrent Thyroid Cancer;   Recurrent Transitional Cell Cancer of the Renal Pelvis and Ureter;   Recurrent Urethral Cancer;   Recurrent Vaginal Cancer;   Recurrent Vulvar Cancer;   Skin Metastases;   Small Intestine Adenocarcinoma;   Somatostatinoma;   Stage III Adenoid Cystic Carcinoma of the Oral Cavity;   Stage III Adrenocortical Carcinoma;   Stage III Bladder Cancer;   Stage III Cervical Cancer;   Stage III Colon Cancer;   Stage III Endometrial Carcinoma;   Stage III Esophageal Cancer;   Stage III Follicular Thyroid Cancer;   Stage III Gastric Cancer;   Stage III Malignant Testicular Germ Cell Tumor;   Stage III Mucoepidermoid Carcinoma of the Oral Cavity;   Stage III Ovarian Epithelial Cancer;   Stage III Pancreatic Cancer;   Stage III Papillary Thyroid Cancer;   Stage III Prostate Cancer;   Stage III Rectal Cancer;   Stage III Renal Cell Cancer;   Stage III Salivary Gland Cancer;   Stage III Squamous Cell Carcinoma of the Larynx;   Stage III Squamous Cell Carcinoma of the Lip and Oral Cavity;   Stage III Squamous Cell Carcinoma of the Nasopharynx;   Stage III Squamous Cell Carcinoma of the Oropharynx;   Stage III Vaginal Cancer;   Stage III Vulvar Cancer;   Stage IIIA Anal Cancer;   Stage IIIA Breast Cancer;   Stage IIIA Non-small Cell Lung Cancer;   Stage IIIB Anal Cancer;   Stage IIIB Breast Cancer;   Stage IIIB Non-small Cell Lung Cancer;   Stage IV Adenoid Cystic Carcinoma of the Oral Cavity;   Stage IV Adrenocortical Carcinoma;   Stage IV Anal Cancer;   Stage IV Bladder Cancer;   Stage IV Breast Cancer;   Stage IV Colon Cancer;   Stage IV Endometrial Carcinoma;   Stage IV Esophageal Cancer;   Stage IV Follicular Thyroid Cancer;   Stage IV Gastric Cancer;   Stage IV Mucoepidermoid Carcinoma of the Oral Cavity;   Stage IV Non-small Cell Lung Cancer;   Stage IV Ovarian Epithelial Cancer;   Stage IV Pancreatic Cancer;   Stage IV Papillary Thyroid Cancer;   Stage IV Prostate Cancer;   Stage IV Rectal Cancer;   Stage IV Renal Cell Cancer;   Stage IV Salivary Gland Cancer;   Stage IV Squamous Cell Carcinoma of the Larynx;   Stage IV Squamous Cell Carcinoma of the Lip and Oral Cavity;   Stage IV Squamous Cell Carcinoma of the Nasopharynx;   Stage IV Squamous Cell Carcinoma of the Oropharynx;   Stage IVA Cervical Cancer;   Stage IVA Vaginal Cancer;   Stage IVB Cervical Cancer;   Stage IVB Vaginal Cancer;   Stage IVB Vulvar Cancer;   Thyroid Gland Medullary Carcinoma;   Unresectable Extrahepatic Bile Duct Cancer;   Unresectable Gallbladder Cancer;   Urethral Cancer Associated With Invasive Bladder Cancer;   WDHA Syndrome
Interventions: Biological: recombinant interleukin-12;   Biological: ABI-007/carboplatin/trastuzumab
9 Recruiting Veliparib and Pegylated Liposomal Doxorubicin Hydrochloride in Treating Patients With Recurrent Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer or Metastatic Breast Cancer
Conditions: Estrogen Receptor-negative Breast Cancer;   HER2-negative Breast Cancer;   Male Breast Cancer;   Progesterone Receptor-negative Breast Cancer;   Recurrent Breast Cancer;   Recurrent Fallopian Tube Cancer;   Recurrent Ovarian Epithelial Cancer;   Recurrent Primary Peritoneal Cavity Cancer;   Stage IV Breast Cancer;   Triple-negative Breast Cancer
Interventions: Drug: veliparib;   Drug: pegylated liposomal doxorubicin hydrochloride;   Other: pharmacological study;   Other: laboratory biomarker analysis
10 Active, not recruiting Temsirolimus and Vinorelbine Ditartrate in Treating Patients With Unresectable or Metastatic Solid Tumors
Conditions: Extensive Stage Small Cell Lung Cancer;   Hereditary Paraganglioma;   Male Breast Cancer;   Malignant Paraganglioma;   Metastatic Gastrointestinal Carcinoid Tumor;   Metastatic Pheochromocytoma;   Pancreatic Polypeptide Tumor;   Recurrent Breast Cancer;   Recurrent Cervical Cancer;   Recurrent Endometrial Carcinoma;   Recurrent Gastrointestinal Carcinoid Tumor;   Recurrent Islet Cell Carcinoma;   Recurrent Neuroendocrine Carcinoma of the Skin;   Recurrent Non-small Cell Lung Cancer;   Recurrent Ovarian Epithelial Cancer;   Recurrent Ovarian Germ Cell Tumor;   Recurrent Pheochromocytoma;   Recurrent Prostate Cancer;   Recurrent Renal Cell Cancer;   Recurrent Small Cell Lung Cancer;   Recurrent Uterine Sarcoma;   Regional Gastrointestinal Carcinoid Tumor;   Regional Pheochromocytoma;   Stage III Cervical Cancer;   Stage III Endometrial Carcinoma;   Stage III Neuroendocrine Carcinoma of the Skin;   Stage III Ovarian Epithelial Cancer;   Stage III Ovarian Germ Cell Tumor;   Stage III Prostate Cancer;   Stage III Renal Cell Cancer;   Stage III Uterine Sarcoma;   Stage IIIA Breast Cancer;   Stage IIIA Non-small Cell Lung Cancer;   Stage IIIB Breast Cancer;   Stage IIIB Non-small Cell Lung Cancer;   Stage IIIC Breast Cancer;   Stage IV Breast Cancer;   Stage IV Endometrial Carcinoma;   Stage IV Neuroendocrine Carcinoma of the Skin;   Stage IV Non-small Cell Lung Cancer;   Stage IV Ovarian Epithelial Cancer;   Stage IV Ovarian Germ Cell Tumor;   Stage IV Prostate Cancer;   Stage IV Renal Cell Cancer;   Stage IV Uterine Sarcoma;   Stage IVA Cervical Cancer;   Stage IVB Cervical Cancer;   Thyroid Gland Medullary Carcinoma
Interventions: Drug: temsirolimus;   Drug: vinorelbine ditartrate
11 Active, not recruiting Veliparib in Treating Patients With Malignant Solid Tumors That Did Not Respond to Previous Therapy
Conditions: BRCA1 Mutation Carrier;   BRCA2 Mutation Carrier;   Estrogen Receptor-negative Breast Cancer;   HER2-negative Breast Cancer;   Hereditary Breast/Ovarian Cancer (BRCA1, BRCA2);   Male Breast Cancer;   Progesterone Receptor-negative Breast Cancer;   Recurrent Breast Cancer;   Recurrent Fallopian Tube Cancer;   Recurrent Ovarian Epithelial Cancer;   Recurrent Pancreatic Cancer;   Recurrent Primary Peritoneal Cavity Cancer;   Recurrent Prostate Cancer;   Triple-negative Breast Cancer;   Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Drug: veliparib;   Other: pharmacological study;   Other: laboratory biomarker analysis
12 Active, not recruiting Topical Imiquimod and Abraxane in Treating Patients With Advanced Breast Cancer
Conditions: Male Breast Cancer;   Recurrent Breast Cancer;   Skin Metastases;   Stage IV Breast Cancer
Interventions: Drug: imiquimod;   Drug: Abraxane;   Other: laboratory biomarker analysis;   Genetic: RNA analysis;   Other: immunoenzyme technique
13 Recruiting Omega-3 Fatty Acid in Treating Patients With Stage I-III Breast Cancer
Conditions: Ductal Breast Carcinoma in Situ;   Lobular Breast Carcinoma in Situ;   Male Breast Cancer;   Stage IA Breast Cancer;   Stage IB Breast Cancer;   Stage II Breast Cancer;   Stage IIIA Breast Cancer;   Stage IIIB Breast Cancer;   Stage IIIC Breast Cancer
Interventions: Dietary Supplement: omega-3 fatty acid;   Other: placebo;   Other: laboratory biomarker analysis
14 Not yet recruiting Vaccine Therapy in Treating Patients With HER2-Negative Stage III-IV Breast Cancer
Conditions: HER2-negative Breast Cancer;   Male Breast Cancer;   Recurrent Breast Cancer;   Stage IIIA Breast Cancer;   Stage IIIB Breast Cancer;   Stage IIIC Breast Cancer;   Stage IV Breast Cancer
Interventions: Biological: CD105/Yb-1/SOX2/CDH3/MDM2 multiplasmid vaccine;   Other: laboratory biomarker analysis
15 Terminated Trastuzumab and Flavopiridol in Treating Patients With Metastatic Breast Cancer
Conditions: HER2-positive Breast Cancer;   Male Breast Cancer;   Recurrent Breast Cancer;   Stage IV Breast Cancer
Interventions: Biological: trastuzumab;   Drug: alvocidib;   Other: laboratory biomarker analysis;   Other: pharmacological study
16 Active, not recruiting Azacitidine and Entinostat in Treating Patients With Advanced Breast Cancer
Conditions: Estrogen Receptor-negative Breast Cancer;   Estrogen Receptor-positive Breast Cancer;   HER2-negative Breast Cancer;   Male Breast Cancer;   Progesterone Receptor-negative Breast Cancer;   Recurrent Breast Cancer;   Stage IIIC Breast Cancer;   Stage IV Breast Cancer;   Triple-negative Breast Cancer
Interventions: Drug: entinostat;   Drug: azacitidine;   Other: laboratory biomarker analysis;   Other: pharmacological study
17 Active, not recruiting Veliparib, Cisplatin, and Vinorelbine Ditartrate in Treating Patients With Recurrent and/or Metastatic Breast Cancer
Conditions: Estrogen Receptor-negative Breast Cancer;   HER2-negative Breast Cancer;   Hereditary Breast/Ovarian Cancer - BRCA1;   Hereditary Breast/Ovarian Cancer - BRCA2;   Male Breast Cancer;   Progesterone Receptor-negative Breast Cancer;   Recurrent Breast Cancer;   Stage IV Breast Cancer;   Triple-negative Breast Cancer
Interventions: Drug: veliparib;   Drug: cisplatin;   Drug: vinorelbine tartrate;   Other: laboratory biomarker analysis;   Other: pharmacological study
18 Terminated Endoscopic Breast Surgery in Treating Patients With Breast Cancer
Conditions: Male Breast Cancer;   Recurrent Breast Cancer;   Stage IA Breast Cancer;   Stage IB Breast Cancer;   Stage II Breast Cancer;   Stage IIIA Breast Cancer;   Stage IIIB Breast Cancer;   Stage IIIC Breast Cancer;   Stage IV Breast Cancer
Interventions: Procedure: endoscopic surgery;   Procedure: quality-of-life assessment
19 Recruiting FLT PET in Measuring Treatment Response in Patients With Newly Diagnosed Estrogen Receptor-Positive, HER2-Negative Stage I-III Breast Cancer
Conditions: Estrogen Receptor-positive Breast Cancer;   HER2-negative Breast Cancer;   Male Breast Cancer;   Stage IA Breast Cancer;   Stage IB Breast Cancer;   Stage II Breast Cancer;   Stage IIIA Breast Cancer;   Stage IIIB Breast Cancer;   Stage IIIC Breast Cancer
Interventions: Drug: fluorine F 18 fluorothymidine;   Procedure: positron emission tomography;   Other: laboratory biomarker analysis
20 Active, not recruiting Tipifarnib and Combination Chemotherapy in Treating Patients With Stage II or Stage III Breast Cancer
Conditions: Breast Cancer;   Male Breast Cancer;   Stage II Breast Cancer;   Stage IIIA Breast Cancer;   Stage IIIB Breast Cancer;   Stage IIIC Breast Cancer
Interventions: Drug: tipifarnib;   Drug: paclitaxel;   Drug: doxorubicin hydrochloride;   Drug: cyclophosphamide;   Drug: pegfilgrastim;   Procedure: conventional surgery;   Procedure: axillary lymph node dissection

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years